Step by Step

INTRODUCTION

ABIM MOC Activity ID

3/14/2017 MGR: Randomized trials of chemotherapy for hormone-naïve metastatic prostate cancer: be careful what you wish for & Endocrine therapy duration updates: too much of a good thing?

QUIZ

EVALUATION

CERTIFICATE

INTRODUCTION

Credit Hours: CME 1.00

Target Audience:

Faculty, residents, fellows, and community physicians in General Internal Medicine and subspecialties.

Educational Objectives:

Upon completion of this activity, participants should be able to:

  • Describe data supporting early chemotherapy in metastatic prostate cancer.
  • Review selection of patients for early chemotherapy for metastatic prostate cancer.
  • Identify risk factors for chemotherapy toxicity.
  • Review history of endocrine treatment
  • Describe difference in pre and post menopausal breast cancer.
  • Review new and updates in hormonal therapy.

Suggested Additional Reading:

  1. Gnant, et al, Brit J Cancer, 2013.
  2. Burstein HJ. J Clin Oncol 2014 32(21):2255-69.

Authors:
Leonard Appleman, MD, PhD — Associate Professor of Medicine Division of Hematology/Oncology, UPMC
Dr. Appleman receives grant/research support from Astellas BMS Bayer, Exelixis, Medivation, Cougar, Agensys, Pfizer, and Roche.
Shannon Puhalla, MD — Assistant Professor of Medicine Division of Hematology/Oncology, UPMC
Dr. Puhalla receives grant/research support from Abbvie, Pfizer, Lilly, Novartis, Incyte, Covance-Bayer, Eisai. She is a consultant with Abbvie, Medimmune, Alldex, and a board member with Alldex (DSMB)
Authors disclosure of relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients is listed above. No other planners, members of the planning committee, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.

The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Pittsburgh School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits. Each physician should only claim credit commensurate with the extent of their participation in the activity.

The University of Pittsburgh is an affirmative action, equal opportunity institution.